These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 29668208)

  • 1. Cost sharing and branded antidepressant initiation among patients treated with generics.
    Buxbaum JD; Chernew ME; Bonafede M; Vlahiotis A; Walter D; Mucha L; Fendrick AM
    Am J Manag Care; 2018 Apr; 24(4):180-186. PubMed ID: 29668208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discontinuation rates and health care costs in adult patients starting generic versus brand SSRI or SNRI antidepressants in commercial health plans.
    Vlahiotis A; Devine ST; Eichholz J; Kautzner A
    J Manag Care Pharm; 2011 Mar; 17(2):123-32. PubMed ID: 21348545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of Newer Antidepressant Medications in U.S. Commercial Health Plans.
    Hodgkin D; Horgan CM; Creedon TB; Merrick EL; Stewart MT
    J Ment Health Policy Econ; 2015 Dec; 18(4):165-73. PubMed ID: 26729008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship of antidepressant prescribing concentration to treatment duration and cost.
    Hodgkin D; Merrick EL; Hiatt D
    J Ment Health Policy Econ; 2012 Mar; 15(1):3-11. PubMed ID: 22611088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient, physician, pharmacy, and pharmacy benefit design factors related to generic medication use.
    Shrank WH; Stedman M; Ettner SL; DeLapp D; Dirstine J; Brookhart MA; Fischer MA; Avorn J; Asch SM
    J Gen Intern Med; 2007 Sep; 22(9):1298-304. PubMed ID: 17647066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effects of Cost Sharing on Adherence to Medications Prescribed for Concurrent Use: Do Definitions Matter?
    Sacks NC; Burgess JF; Cabral HJ; McDonnell ME; Pizer SD
    J Manag Care Spec Pharm; 2015 Aug; 21(8):678-87. PubMed ID: 26233540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analyzing generic and branded substitution patterns in the Netherlands using prescription data.
    Pechlivanoglou P; van der Veen WJ; Bos JH; Postma MJ
    BMC Health Serv Res; 2011 Apr; 11():89. PubMed ID: 21524312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization and drug cost outcomes of a step-therapy edit for generic antidepressants in an HMO in an integrated health system.
    Dunn JD; Cannon E; Mitchell MP; Curtiss FR
    J Manag Care Pharm; 2006 May; 12(4):294-302. PubMed ID: 16792435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece.
    Maniadakis N; Kourlaba G; Mougiakos T; Chatzimanolis I; Jonsson L
    BMC Health Serv Res; 2013 May; 13():173. PubMed ID: 23663281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of medicare part D plan features on use of generic drugs.
    Tang Y; Gellad WF; Men A; Donohue JM
    Med Care; 2014 Jun; 52(6):541-8. PubMed ID: 24824538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is associated with increased side effects and lower perceived efficacy following switching to a generic medicine? A New Zealand cross-sectional patient survey.
    MacKrill K; Petrie KJ
    BMJ Open; 2018 Oct; 8(10):e023667. PubMed ID: 30341138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilization, price, and spending trends for antidepressants in the US Medicaid Program.
    Chen Y; Kelton CM; Jing Y; Guo JJ; Li X; Patel NC
    Res Social Adm Pharm; 2008 Sep; 4(3):244-57. PubMed ID: 18794035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Costs associated with changes in antidepressant treatment in a managed care population with major depressive disorder.
    Schultz J; Joish V
    Psychiatr Serv; 2009 Dec; 60(12):1604-11. PubMed ID: 19952150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Choice of generic versus brand-name antidepressants in a regulated prescription drug market: evidence from Taiwan.
    Liu YM; Ou HT; Yang YK
    J Ment Health Policy Econ; 2014 Dec; 17(4):163-72. PubMed ID: 25599280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generic and therapeutic statin switches and disruptions in therapy.
    Chapman RH; Benner JS; Girase P; Benigno M; Axelsen K; Liu LZ; Nichol MB
    Curr Med Res Opin; 2009 May; 25(5):1247-60. PubMed ID: 19344292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence and Persistence Across Antidepressant Therapeutic Classes: A Retrospective Claims Analysis Among Insured US Patients with Major Depressive Disorder (MDD).
    Keyloun KR; Hansen RN; Hepp Z; Gillard P; Thase ME; Devine EB
    CNS Drugs; 2017 May; 31(5):421-432. PubMed ID: 28378157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association of race, comorbid anxiety, and antidepressant adherence among Medicaid enrollees with major depressive disorder.
    Wu CH; Erickson SR; Piette JD; Balkrishnan R
    Res Social Adm Pharm; 2012; 8(3):193-205. PubMed ID: 21955808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antidepressant Medication Prescribing Practices for Treatment of Major Depressive Disorder.
    Treviño LA; Ruble MW; Treviño K; Weinstein LM; Gresky DP
    Psychiatr Serv; 2017 Feb; 68(2):199-202. PubMed ID: 27691378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment patterns, healthcare resource utilization, and costs following first-line antidepressant treatment in major depressive disorder: a retrospective US claims database analysis.
    Gauthier G; Guérin A; Zhdanava M; Jacobson W; Nomikos G; Merikle E; François C; Perez V
    BMC Psychiatry; 2017 Jun; 17(1):222. PubMed ID: 28629442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does antidepressant step therapy fuel the law of unintended consequences?
    Greden JF
    Am J Psychiatry; 2010 Oct; 167(10):1148-51. PubMed ID: 20889657
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.